Prevalence and prognosis of patients with breast cancer eligible for adjuvant abemaciclib or ribociclib: a nationwide population-based studyResearch in context

Summary: Background: Nationwide studies on the prevalence, characteristics and long-term prognosis of patients with early breast cancer and a potential indication for adjuvant CDK4/6 inhibitors are lacking. Methods: We leveraged a prospectively collected nationwide cohort of all patients treated fo...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Xingrong Liu, Behnaz Binicy, Balazs Acs, Louise Eriksson Bergman, Sibylle Loibl, Michael Gnant, Michael Untch, Antonios Valachis, Jonas Bergh, Johan Hartman, Theodoros Foukakis, Alexios Matikas
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Elsevier 2025-12-01
Serie:	The Lancet Regional Health. Europe
Soggetti:	Abemaciclib Adjuvant Breast cancer CDK4/6 inhibitors monarchE NATALEE
Accesso online:	http://www.sciencedirect.com/science/article/pii/S2666776225002637
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!